Skip to main content

ORIGINAL RESEARCH article

Front. Oncol.
Sec. Cancer Genetics
Volume 14 - 2024 | doi: 10.3389/fonc.2024.1378019
This article is part of the Research Topic Women in Cancer Genetics Vol III: 2023 View all 3 articles

Outcomes and the effect of PGT-M in women with hormone-related hereditary tumor syndrome

Provisionally accepted
Ding-Ran WANG Ding-Ran WANG Xueling Song Xueling Song Xiaohui Zhu Xiaohui Zhu Liying Yan Liying Yan Xu Zhi Xu Zhi Jie Yan Jie Yan Huamao Liang Huamao Liang *JIE QIAO JIE QIAO
  • Peking University Third Hospital, Haidian, China

The final, formatted version of the article will be published soon.

    To review the outcome of PGT-M in hormone-related hereditary tumor syndrome and evaluate the effect of ovarian induction on tumor growth in those patients.Medical records of PGT-M were retrospectively analyzed in patients with hormone-related heritage tumors in our reproductive center. A total of eleven women with hereditary breast and ovarian cancer (HBOC) (including BRCA1/2 mutation carriers), and Lynch syndrome (including MMR gene mutation carriers) were included. Thirteen IVF/PGT-M cycles were performed. Eleven for PGT-M and two for fertility preservation. The ovulation protocol, numbers of oocytes retrieved and two pronuclei (2PN) zygotes, PGT-M results, and clinical outcomes were analyzed. Tumor progression was also estimated by comparing transvaginal ultrasound (TVS), MR, CT, or colonoscopy according to the follow-up requirements of different tumors.Eleven IVF/PGT-M cycles were performed with an antagonist protocol; Two cycles were performed with a mild stimulation protocol. The total dose of gonadotropin (Gn) was 1827 IU per patient (range from 1200 to 2625 IU). The median number of oocytes retrieved was 13 (range from 4 to 30), and the median number of 2PN zygotes was 8 (range from 2 to 16). A total of 32 embryos underwent PGT-M, and 9 (28.1%) embryos were suitable for transfer. Six transfer cycles were performed, and 5 cycles got clinical pregnancy (83%) with five newborns (83%). The follow-up examinations conducted 10-18 months after PGT-M/delivery revealed no new lesions or tumor progression.PGT-M results can provide important information for improving the consultation of hormonerelated heritage tumor patients regarding their fertility preservation and reproductive options. Ovarian induction for women with hormone-related hereditary tumor syndrome is not associated with tumor progression.

    Keywords: PGT, Hereditary tumor syndrome, Fertility Preservation, HBOC (hereditary breast and ovarian cancer), Lynch syndrome (hereditary nonpolyposis colorectal cancer)

    Received: 29 Jan 2024; Accepted: 25 Apr 2024.

    Copyright: © 2024 WANG, Song, Zhu, Yan, Zhi, Yan, Liang and QIAO. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Huamao Liang, Peking University Third Hospital, Haidian, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.